Abstract: The invention relates to a pharmaceutical product comprising therapeutically effective amounts of: (a) an ALK inhibitor or an antibody-drug conjugate directed to the ALK receptor, and (b) a TNF-related apoptosis-inducing ligand (TRAIL) receptor agonist.

Abstract: The invention relates to a method for the treatment of cancer by changing the intracellular activity of cdc42. The activity can be increased by treatment with small molecules, for instance, treatment with non-hydrolyzable GTP-analogues of cdc-42. Also, the activity can be increased by inhibiting nm23-H1 and/or nm23-H2, which are factors having an inhibitory effect on the expression and/or activity of cdc-42. It is also shown that a decrease in the intracellular activity of cdc-42 has a beneficial effect. Further embodiments of the invention are the compounds for use in such methods, pharmaceutical preparations comprising such compounds and use of such compounds for the preparation of a medicament for treatment of cancer.

Abstract: The invention discloses a catalog of targets of the myc oncogene family identified by Serial Analysis of Gene Expression. The invention also discloses a method for analyzing myc downstream targets in view of the full context of myc induced changes in gene expression. The invention further discloses a method for the treatment of cancer comprising modulating a myc-dependent downstream gene capable of supporting an essentially neoplastic characteristic of the cancer. The invention additionally discloses a method of screening to identify drugs that interfere with myc downstream effects.